GEN News Highlights: Dec 2, 2010

Bruker to Provide MS-Based Microbial Identification Tool to Public Hospital Network of Paris

(Page 1 of 1)

    Bruker will be supplying Assistance Publique Hôpitaux de Paris (APHP) with the company’s IVD MALDI Biotyper. It will function as the exclusive MALDI-TOF mass spectrometry-based microbial identification tool.

    Three hospitals—Bichat, Cochin, and Lariboisière—have each already ordered an IVD MALDI Biotyper system. Bruker notes that two other APHP hospitals have been working with its MALDI-TOF mass spectrometers for several years. The APHP hospitals will use the IVD MALDI Biotyper for identification of micro-organisms such as Gram-negative bacteria, Gram-positive bacteria, and yeasts.

    “We want to use MALDI-TOF mass spectrometry identification in routine clinical microbiology applications to achieve the precision in bacterial identification that could otherwise only be obtained using time-consuming sequence based identification,” says Martin Rottman, associate professor of microbiology at University of Versailles and Hospital Raymond Poincaré. “Indeed the currently available biochemical methods fail to identify many micro-organisms involved in bone and joint infections.”

    The MALDI Biotyper solution enables identification, taxonomical classification, or dereplication of microorganisms like bacteria, yeasts, and fungi. Classification and identification of microorganisms is achieved using high-throughput MALDI-TOF mass spectrometry.

    Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology.

    The workflow can also be applied on all linear-only Bruker MALDI-TOF mass spectrometers under IVD-CE, i.e., the microflow benchtop instrument as well as the floor-standing, high-throughput autoflex. The MALDI Biotyper method requires minimal sample preparation efforts and offers low cost per sample, Bruker states.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll